Articles

11. Veteran Guidance On The CMO Selection Process From James Bruno 11/11/2011

    Life Science Leader magazine put together an executive roundtable article on the CMO selection process for a 2011 special supplement. The intent – to gain a better understanding of the some of the challenges faced during the partnering and provide insights on how to overcome. I received some great responses from James Bruno managing director, Chemical and Pharmaceutical Solutions and Chemical Consultants. By Rob Wright

12. Alkermes Contract Pharma Services 9/28/2011

    With Alkermes Contract Pharma Services, you have the opportunity to outsource your development, scale-up and manufacturing requirements to a trusted, experienced and dedicated expert in outsourcing services.

13. White Paper: Clinical Trial Material Production And Testing: What Your CMO Is Not Telling You 6/7/2011
    Manufacturing clinical trial material (CTM), and the costs for the associated fill/finish and release work, most likely are not the costliest portions of the pharmaceutical process chain. By Alexander Mello, Director, Project Management
14. White Paper: Outsourcing Insights 5/19/2011
    If you have been in the pharmaceutical industry for an extended period of time, you’ve likely noticed how CROs have evolved from offering basic support to providing a wide range of clinical, central laboratory, and analytical services to meet market demands. By Victor Coker, director of business intelligence, Nice Insight
15. Outsourcing Insights 5/19/2011

    If you have been in the pharmaceutical industry for an extended period of time, you’ve likely noticed how CROs have evolved from offering basic support to providing a wide range of clinical, central laboratory, and analytical services to meet market demands. By Victor Coker, director of business intelligence, Nice Insight

16. Brochure: Custom Synthesis 12/6/2010

    PharmaZell draws upon a long history of successful custom synthesis projects, performed on a proprietary basis for pharmaceutical companies worldwide.

17. Comprehensive Preclinical Development Program 4/9/2010
    Aptuit was asked to conduct an extended package of preclinical studies within a short time frame. As the critical studies are dependent on the results of earlier work in the package (for example, initiation of the 28 day toxicology studies are dependent on the completion of bioanalytical method development, dose range finding, etc.) not only scheduling, but adherence to the schedule was the major risk to achievement of the overall aim, and on time filing to the regulator. By Aptuit, Inc.
18. Product Development Of An Inhaled Protein 4/9/2010
    A small biotechnology company in the United States turned to Aptuit to support the development of their inhaled respiratory product. They had added confidence that their limited in-house capability would benefit from Aptuit’s substantial experience and capabilities in respiratory science projects, fulfilling their need for first-in-class capabilities in manufacturing, clinical packaging and logistics, bio-analytics and respiratory analytics. By Aptuit, Inc.